Spondyloarthritis & psoriatic arthritis
Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
Main finding · Shorter UST persistence (time to discontinuation)Result — go to the resultHazard ratio 1.98Authors' conclusion
The negative impact of comorbidities on treatment persistence identified in this study emphasises the need for patient-centric, multidisciplinary care in screening for and managing comorbidities in psoriasis and PsA treatment.
Study context
- Population
- Patients receiving ustekinumab (UST) or conventional systemic DMARDs in the British Association of Dermatologists Biologic and Immunomodulators Register
- Participants
- 9,057 patients
- Exposure
- Plaque psoriasis with concomitant PsA vs psoriasis alone, receiving UST
- Outcome
- Time to discontinuation of UST (UST persistence)
- Follow-up
- 10-year follow-up
Methodological detailsobservational, registry-based (BADBIR), multivariable Cox regression, Kaplan-Meier analyses, generalised linear mixed models
- Observational
- Registry-based (BADBIR)
- Multivariable Cox regression
- Kaplan-Meier analyses
- Generalised linear mixed models
Main finding
As reported in the abstract
Shorter UST persistence (time to discontinuation)
Hazard ratio
1.98
- Male sex (vs female) associated with UST persistence, HR
- 0.72
- Depression associated with shorter UST persistence, HR
- 1.21
Observational data: associations, not effects.
Further findings
Baseline comorbidity burden
- Greater comorbidity burden (hypertension, diabetes, obesity, depression) and greater inability to work in PsA than psoriasis cohort
UST persistence by Psoriasis Area and Severity Index (PASI) strata and prior biologic exposure
- PsA showed a differential association with UST persistence by PASI strata and prior biologic exposure
Quality of life
- Quality of life negatively impacted by depression and PsA
Original publication
Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study. RMD Open. Published 17 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →